6 questions answered from cited research · Plain language
Epysqli (eculizumab-sbja) is FDA-approved for generalized myasthenia gravis only in adult patients who test positive for anti-acetylcholine receptor (AChR) antibodies.
Read the full answer →Yes, thymoma can be associated with both myasthenia gravis and stiff person syndrome, though this combination is very rare.
Read the full answer →Yes, complement inhibitors (eculizumab, ravulizumab, zilucoplan) significantly improve symptoms and daily functioning in AChR antibody-positive generalized myasthenia gravis, based on multiple trials and real-world studies.
Read the full answer →Yes, people with myasthenia gravis have an increased risk of developing autoimmune encephalitis, likely due to shared autoimmune mechanisms and overlapping antibody targets.
Read the full answer →Early research suggests a ketogenic diet may improve symptoms and quality of life in myasthenia gravis, but evidence is limited to one small pilot study.
Read the full answer →Yes, efgartigimod helps improve symptoms in myasthenia gravis patients, with most studies showing clinically meaningful improvements in daily living scores and muscle strength.
Read the full answer →